Monoclonal Antibody Therapy in Treating Patients With Ovarian Cancer or Primary Peritoneal Cancer in Remission Following Surgery and Chemotherapy

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically proven stage IC, II, III, or IV ovarian epithelial carcinoma or primary peritoneal serous carcinoma
• Prior complete response to 1 platinum-based chemotherapy regimen consisting of at least 5 courses
• * Absence of disease on physical and radiological exam (CT scan/MRI)
• * CA 125 normal
• * No visible evidence of malignant disease on second-look laparoscopy
• No disease relapse even if complete response to a second course of chemotherapy
• Prior bilateral oophorectomy with or without salpingectomy, omentectomy, and total or partial abdominal hysterectomy required
• No known metastases
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Performance status:
• ECOG 0-2
• Life expectancy:
• At least 3 months
• Hematopoietic:
• WBC at least 3,000/mm\^3
• Platelet count at least 100,000/mm\^3
• Hemoglobin at least 10.0 g/dL
• Hepatic:
• SGOT/SGPT no greater than 2 times upper limit of normal
• Renal:
• Creatinine no greater than 2.0 mg/dL
• Other:
• No other malignancy except basal cell skin cancer
• No serious physical or psychiatric disease that would preclude study entry
• No significant loculation that would preclude good distribution of study medication
• Human antimouse antibody negative
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• No prior murine antibody
• Chemotherapy:
• See Disease Characteristics
• No more than 4-8 weeks since prior chemotherapy
• Endocrine therapy:
• Not specified
• Radiotherapy:
• Not specified
• Surgery:
• See Disease Characteristics
• Other:
• No concurrent participation in other trials involving adjuvant cancer treatment
• No other concurrent experimental therapies